SOLVD - treatment arm
Last reviewed 01/2018
This multicentre, randomised, double-blind, placebo-controlled trial enrolled 2569 patients with reduced left ventricular function (ejection fraction <35%) and symptomatic heart failure.
The addition of enalapril to the conventional heart failure therapy was found to significantly:
- reduce mortality by 16%
- reduce hospitalisation for heart failure by 26%
- SOLVD Investigators. (1991). N Engl J Med. 325, 293-302.